Carolyn Funke
Medical · Westminster, MDNPI 1053770636
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 484 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 484 payments — averaging $17.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Pfizer$817
- AstraZeneca$652
- Novo Nordisk$635
- Lilly USA, LLC$551
- Amgen$477
- plus $4K from 30 others
What the payments were for
- Food & beverage$8,38298%
- Education$1442%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 79 | $1,252 |
| Pfizer | 49 | $817 |
| AstraZeneca | 35 | $652 |
| Novo Nordisk | 36 | $635 |
| Lilly USA, LLC | 39 | $551 |
| Amgen | 29 | $477 |
| Boehringer Ingelheim | 23 | $471 |
| Astellas Pharma US Inc | 22 | $450 |
| GSK | 22 | $383 |
| Teva Pharmaceuticals USA, Inc. | 14 | $327 |
| Biohaven Pharmaceuticals, Inc. | 18 | $302 |
| Biohaven Pharmaceutical Holding Company Ltd. | 14 | $255 |
| Esperion Therapeutics, Inc. | 13 | $255 |
| Merck | 16 | $243 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $160 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $135 |
| Johnson & Johnson | 6 | $111 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $110 |
| Bayer | 5 | $103 |
| Exact Sciences | 5 | $99 |
| Sumitomo Pharma America, Inc. | 4 | $93 |
| Grifols USA, LLC | 5 | $90 |
| Amarin Pharma, Inc. | 4 | $81 |
| Axsome Therapeutics, Inc. | 3 | $74 |
| E.r. Squibb & Sons, L.L.C. | 3 | $64 |
| Sunovion Pharmaceuticals Inc. | 3 | $59 |
| Bausch Health US, LLC | 2 | $39 |
| Eisai Inc. | 2 | $38 |
| IBSA Pharma Inc. | 2 | $35 |
| Vanda Pharmaceuticals Inc. | 1 | $31 |
| Currax Pharmaceuticals LLC | 2 | $30 |
| Almatica Pharma LLC | 1 | $26 |
| Tactile Systems Technology Inc | 1 | $22 |
| Collegium Pharmaceutical, Inc. | 1 | $22 |
| PBG Puerto Rico LLC | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
How this compares
$8,526 in reported general payments places this provider in the 90th percentile of 543 medical providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 22 | $30,133 |
| JardianceEmpagliflozin | 15 | $20,196 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $20,073 |
| XareltoRivaroxaban | 12 | $19,636 |
| EliquisApixaban | 15 | $18,303 |
| MounjaroTirzepatide | 13 | $13,152 |
| VascepaIcosapent Ethyl | 15 | $11,249 |
| MotegrityPrucalopride Succinate | 11 | $6,048 |
| SynthroidLevothyroxine Sodium | 34 | $3,961 |
| DexilantDexlansoprazole | 12 | $3,412 |
| Atorvastatin Calcium | 207 | $2,791 |
| Metoprolol Succinate | 85 | $1,775 |
| Niacin ErNiacin | 11 | $1,657 |
| Nebivolol Hcl | 26 | $1,317 |
| Losartan Potassium | 116 | $1,281 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $635 | $30,13322 claims |
| Boehringer IngelheimJardiance | $471 | $20,19615 claims |
| GSKTrelegy Ellipta | $383 | $20,07322 claims |
| Johnson & JohnsonXarelto | $111 | $19,63612 claims |
| PfizerEliquis | $817 | $18,30315 claims |
| Lilly USA, LLCMounjaro | $551 | $13,15213 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity, Dexilant | $160 | $9,45923 claims |
| AbbVieSynthroid | $1,252 | $3,96134 claims |
| Almatica Pharma LLCSertraline Hcl | $26 | $870110 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 543 medical providers in Maryland.
Other medical in Westminster
- Rebecca BowerWestminster$8K
- Victoria TrottStevensville$94K
- Sarah SagorskyBaltimore$68K
- Emily GrisnikLeonardtown$62K
- Jennifer HamiltonBel Air$52K
- Kristina TrunnellFrederick$51K
- Karen ScottAnnapolis$49K
- Nicholas WunderAberdeen$40K
- Sarah JamiesonFrederick$34K
- Jayme WilliamsCatonsville$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.